Persistent tumor cells that survive anticancer therapy can remain viable despite profound suppression of proliferation, yet survival during treatment and recovery after treatment withdrawal are biologically distinct events. This integrative review examines how metabolic state, enzyme regulation, proteome remodeling, nutrient use, and redox control may shape the transition from treatment persistence to renewed proliferative capacity. Evidence published from 2017 through 2026 was synthesized across experimental, multi-omic, metabolic, lineage-tracing, patient-derived, and review studies, with explicit separation of observations obtained during active treatment from those addressing withdrawal, regrowth, or recurrence. The evidence does not support a single metabolic program shared by all persistent tumor cells. Instead, oxidative phosphorylation, fatty-acid oxidation, lipid-peroxide defense, transsulfuration, lipid synthesis, mitophagy, purine signaling, and one-carbon-linked chromatin regulation recur in different combinations according to tumor lineage and treatment context. These observations indicate that metabolic recovery is best understood as a conditional transition requiring compatibility among pre-existing or treatment-induced cell state, enzyme and proteome organization, redox capacity, and accessible nutrient resources. Therapeutic opportunities therefore lie less in identifying one universal persister metabolism than in defining context-specific recovery dependencies that remain actionable when treatment pressure is removed.
